

US traction continues, LatAm growth steady; focus on embarked capex...

About the stock: Caplin derives almost entire revenues through exports with 86% of revenues from Emerging Markets (LatAm + RoW) where it has an end-to-end business model through last mile logistical solutions for its exclusive distributors.

- In the US, overall development pipeline remains robust, with 55+ ANDAs under development with an addressable market in US at over US\$5 billion
- For LatAm markets, it outsources ~45% of products (China: 35%; Indian vendors: 65%) and in-house manufacturing remains at ~55%
- Caplin Steriles caters to the rapidly growing demand for injectable products in the US and other regulated markets

Q4FY23 Results: In line numbers, substantial beat on margins front.

- Revenues grew 14.8% YoY to ₹ 389 crore
- EBITDA grew 24% YoY to ₹ 123.9 crore and margins improved 238 bps YoY to 31.8%
- Adjusted PAT grew 28% YoY to ₹ 101.1 crore

What should investors do? Caplin's share price has grown at 31% CAGR over the past three years.

- Maintain **BUY** due to 1) Consistent growth from legacy LatAm markets and increasing footprints in other geographies, 2) Traction from visible order book in the US and 3) Calculated capex decisions to expand capacity, widen portfolio and backward integration

Target Price and Valuation: Valued at ₹ 900 i.e. 18x P/E on FY25E EPS of ₹ 50.1.

Key triggers for future price performance:

- Execution of the ~₹ 500-550 crore capex towards Caplin Steriles, RoW facility, oncology (OSD & injectable) project and API backward integration
- The launch of new own brands, increased product basket, increased front-end expansion, and an altered product mix will all contribute to the continued growth momentum
- Plans to expand in six major markets of the US, Mexico, Brazil, Europe, Argentina, South Africa and CIS countries with differentiated strategies

Alternate Stock Idea: Apart from Caplin, in our coverage, we like Granules.

- Granules India is a vertically integrated company that manufactures API, intermediates and finished dosages
- BUY with a target price of ₹ 360




Particulars

Particular	Amount
Market Capitalisation	₹ 5320 crore
Debt (FY23)	₹ 5 crore
Cash (FY23)	₹ 493 crore
EV	₹ 4832 crore
52 week H/L	857/575
Equity capital	₹ 15.2 crore
Face value	₹ 2

Shareholding pattern

(in %)	Jun-22	Sep-22	Dec-22	Mar-23
Promoter	68.9	68.9	68.8	70.7
Others	31.1	31.1	31.2	29.3

Price Chart



Recent Event & Key risks

- Softgel capacity expansion
- Key Risk:** (i) Regulatory risks (ii) Slower ramp-up in new markets

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Kushal Shah
kushal.shah@icicisecurities.com

Utkarsh Jain
utkarsh.jain@icicisecurities.com

Key Financial Summary

Key Financials (₹ Crore)	FY21	FY22	FY23	5 year CAGR (FY17-22)	FY24E	FY25E	2 year CAGR (FY23-25E)
Revenues	1061.3	1269.4	1466.7	25.9	1649.1	1854.0	12.4
EBITDA	328.7	394.7	440.0	26.0	490.6	560.8	12.9
EBITDA Margins (%)	31.0	31.1	30.0		29.8	30.3	
Net Profit	242.3	299.8	374.2	25.7	364.4	380.8	0.9
EPS (Adjusted)	31.9	39.5	49.2		48.0	50.1	
PE (x)	22.0	17.7	14.2		14.6	14.0	
RoCE (%)	25.4	25.3	23.4		21.9	19.8	
RoE (%)	20.4	20.2	19.9		16.4	14.8	

Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q4FY23: In line numbers, substantial beat on margins front

- Revenues grew 14.8% YoY to ₹ 389 crore propelled by LatAm 10.1% YoY growth and US grew 54.7% YoY. EBITDA grew 24% YoY to ₹ 123.9 crore, EBITDA margins improved 238 bps YoY to 31.8%. Adjusted PAT grew 27.9% YoY to ₹ 101.1 crore
- The company's new product launches and increased market share from its products aided growth during the quarter. It has also commenced exports to newer markets such as Cambodia, Turkmenistan and Uzbekistan. The strategy to bank on a strong footprint in the smaller LatAm markets, focus on establishing itself in the complex US injectable space besides foraying into bigger LatAm and other global emerging markets has been backed by calculated capex plans to expand existing capacities and greenfield projects. We remain positive on the company's strong earnings profile and focused approach with growth capex

Q4FY23 Earnings Conference Call highlights:

US & Regulated markets:

- The performance was supported by improved business mix: Product supply share - 70% & Milestone (with profit share) - 30%
- Caplin Sterile has made good progress during the period and also touched breakeven at the PAT level. It made EBITDA of ₹ 8.5 crore in Q4FY23 whereas ₹ 20.3 crore for FY23
- It has a healthy order book at ~₹ 250 crore

Emerging markets:

- It delivered decent growth in LatAm
- The CP-1 plant's Softgel expansion concluded and commercial exports started in Q4FY23
- The new capacity will touch 2x the current capacity. The management has guided for ~ ₹ 80 crore revenues in FY24
- The company intends to enter the LatAm branding market, specifically in the CNS and CVS divisions. The revenue potential from the same is expected to be at ~₹ 30 crore

Launches:

- It has introduced co-branded products for four of its approved products in the US
- It intends to file all four complex products (three injectables & 1 ophthalmic) with the US and global markets during FY24

Other highlights:

- The management has guided for capex of ~₹ 350 crore for FY24E and FY25E
- The company reported gross margins of ~54% in LatAm
- It has been successful in receiving approvals for certain products in Canada and Australia markets
- Its Vizag facility is expected to go on stream in FY24
- The company hopes to get backward integrated with its own APIs for 70% of all US registrations, which will be a key differentiation for generic injectables
- The work for new oral solid dosages facility at Chennai is likely to commence soon
- The management's focus remains on the current ongoing USFDA inspection at its facility, which will help it further penetrate the US markets
- The company during the period received two tender awards from LatAm for speciality & oncology products to be delivered in H1FY24

Exhibit 1: Variance Analysis

	Q4FY23	Q4FY22	Q3FY23	YoY (%)	QoQ (%)	Comments
Revenue	389.3	339.2	372.0	14.8	4.6	Revenues growth propelled by US business which grew 65% YoY to ₹58 crore.
Raw Material Expenses	176.6	151.9	163.9	16.2	7.7	
Gross margins (%)	54.6	55.2	55.9	-58 bps	-131 bps	
Employee Expenses	36.0	30.2	35.5	19.0	1.3	
Other Expenditure	52.8	57.1	64.3	-7.7	-17.9	
Total Operating Expenditure	265.4	239.3	263.7	10.9	0.6	
EBITDA	123.9	99.9	108.3	24.0	14.4	
EBITDA (%)	31.8	29.5	29.1	238 bps	272 bps	
Interest	0.2	0.1	0.4	187.5	-36.1	
Depreciation	11.1	11.5	11.4	-2.8	-2.6	
Other income	11.4	11.5	14.2	-1.0	-19.4	
PBT before EO	124.0	99.9	110.7	24.1	12.0	
Less: Exceptional Items	0.0	0.0	0.0	0.0	0.0	
PBT	124.0	99.9	110.7	24.1	12.0	
Tax	22.8	19.1	14.4	19.5	59.0	
MI & Share of loss/ (gain) asso.	0.1	1.8	-0.1	-95.5	LP	
Adjusted Net Profit	101.1	79.1	96.4	27.9	4.9	
Key Metrics						
LaTAm & Africa	334.8	304.0	319.9	10.1	4.6	
US	58.0	35.2	52.1	64.6	11.4	

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY23			FY24E			FY25E			Comments
	Old	New	Change	Old	New	Change	Old	New	Change	
Revenue	1,456.9	1,466.7	0.7	1,659.0	1,649.1	-0.6	1,865.3	1,854.0	-0.6	
EBITDA	429.0	440.0	2.6	493.6	490.6	-0.6	564.2	560.8	-0.6	
EBITDA Margin (%)	29.4	30.0	56 bps	29.8	29.8	0 bps	30.3	30.3	0 bps	
PAT	371.1	374.2	0.8	363.7	364.4	0.2	411.3	380.8	-7.4	
EPS (₹)	48.8	49.2	0.8	47.9	48.0	0.2	54.1	50.1	-7.4	

Source: ICICI Direct Research

Exhibit 3: Financial Summary

	Revenues	Growth	EPS	Growth	P/E	EV/EBITDA	RoE	RoCE
	(₹ crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY21	1061	22.9	31.9	12.6	22.0	14.8	20.4	25.4
FY22	1269	19.6	39.5	23.8	17.7	12.2	20.2	25.3
FY23	1467	15.5	49.2	24.8	14.2	10.6	19.9	23.4
FY24E	1649	12.4	48.0	-2.6	14.6	9.3	16.4	21.9
FY25E	1854	12.4	50.1	4.5	14.0	7.7	14.8	19.8


Source: ICICI Direct Research

Exhibit 4: Trends in Quarterly Performance

(₹ crore)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	YoY (%)	QoQ (%)
Total Operating Incom	215.2	240.1	268.1	274.4	278.7	300.4	303.5	326.2	339.2	346.3	359.1	372.0	389.3	14.8	4.6
Raw Material Expen	111.4	108.8	120.4	123.9	118.7	136.0	125.8	143.8	151.9	157.2	165.5	163.9	176.6	16.2	7.7
% of Revenue	51.8	45.3	44.9	45.2	42.6	45.3	41.4	44.1	44.8	45.4	46.1	44.1	45.4	58 bps	131 bps
Gross Profit	103.8	131.3	147.8	150.5	160.0	164.5	177.8	182.4	187.3	189.1	193.6	208.1	212.7	13.5	2.2
Gross Profit Margin	48.2	54.7	55.1	54.8	57.4	54.7	58.6	55.9	55.2	54.6	53.9	55.9	54.6	-58 bps	-131 bps
Employee Expenses	18.5	25.9	25.3	25.5	25.9	26.7	29.0	29.4	30.2	32.4	34.0	35.5	36.0	19.0	1.3
% of Revenue	8.6	10.8	9.4	9.3	9.3	8.9	9.5	9.0	8.9	9.4	9.5	9.6	9.2	33 bps	-31 bps
Other Expenditure	31.5	33.8	35.1	41.1	48.5	45.2	47.6	52.0	57.1	54.5	54.0	64.3	52.8	-7.7	-17.9
% of Revenue	14.6	14.1	13.1	15.0	17.4	15.0	15.7	15.9	16.8	15.7	15.0	17.3	13.6	-329 bps	-372 bps
Total Expenditure	161.4	168.5	180.7	190.5	193.0	207.8	202.4	225.2	239.3	244.2	253.5	263.7	265.4	10.9	0.6
% of Revenue	75.0	70.2	67.4	69.4	69.3	69.2	66.7	69.0	70.5	70.5	70.6	70.9	68.2	-238 bps	-272 bps
EBITDA	53.8	71.6	87.4	83.9	85.7	92.6	101.2	101.0	99.9	102.2	105.6	108.3	123.9	24.0	14.4
EBITDA Margin (%)	25.0	29.8	32.6	30.6	30.7	30.8	33.3	31.0	29.5	29.5	29.4	29.1	31.8	238 bps	272 bps
Other Income	19.6	6.5	1.8	5.8	9.5	9.2	8.5	9.5	11.5	13.9	16.5	14.2	11.4	-1.0	-19.4
Interest	0.2	0.5	0.5	0.3	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.4	0.2	187.5	-36.1
Depreciation	8.4	9.0	8.9	9.3	9.9	12.0	11.7	11.7	11.5	11.0	11.5	11.4	11.1	-2.8	-2.6
PBT	64.9	68.6	79.8	80.2	85.0	89.5	97.7	98.7	99.9	105.1	110.5	110.7	124.0	24.1	12.0
Total Tax	16.0	14.1	17.0	14.1	17.1	18.0	20.9	19.4	19.1	18.8	18.4	14.4	22.8	19.5	59.0
Tax rate (%)	24.7	20.5	21.3	17.5	20.1	20.1	21.4	19.6	19.1	17.9	16.7	13.0	18.4	-71 bps	543 bps
PAT	48.9	54.5	56.9	64.5	66.4	70.9	75.0	75.0	79.1	85.0	91.7	96.4	101.1	27.9	4.9
PAT Margin (%)	22.7	22.7	21.2	23.5	23.8	23.6	24.7	23.0	23.3	24.5	25.5	25.9	26.0	266 bps	5 bps


Source: ICICI Direct Research

Exhibit 5: PE Band




Source: ICICI Direct Research

Exhibit 6: Revenues to grow at 12.4% CAGR in FY23-25E




Source: Company, ICICI Direct Research

Exhibit 7: EBITDA & EBITDA margins trend




Source: Company, ICICI Direct Research

Exhibit 8: PAT & PAT margins trend



Source: Company, ICICI Direct Research

Exhibit 9: RoE & RoCE trend



Source: Company, ICICI Direct Research

Financial Summary

Exhibit 10: Profit and loss statement				
	₹ crore			
(Year-end March)	FY22	FY23	FY24E	FY25E
Total Operating Income	1,269.4	1,466.7	1,649.1	1,854.0
Growth (%)	19.6	15.5	12.4	12.4
Raw Material Expenses	557.5	663.2	742.1	825.0
Gross Profit	711.9	803.5	907.0	1,029.0
Gross Profit Margins (%)	56.1	54.8	55.0	55.5
Employee Expenses	115.3	138.0	152.5	171.5
Other Expenditure	201.9	225.5	263.9	296.6
Total Operating Expenditure	874.7	1,026.7	1,158.5	1,293.2
EBITDA	394.7	440.0	490.6	560.8
Growth (%)	20.1	11.5	11.5	14.3
Interest	0.7	0.8	12.6	12.6
Depreciation	46.9	45.0	55.5	111.7
Other Income	38.8	56.0	62.9	70.8
PBT before Exceptional Item	385.8	450.2	485.4	507.2
Less: Exceptional Items	0.0	0.0	0.0	0.0
PBT after Exceptional Items	385.8	450.2	485.4	507.2
Total Tax	77.4	74.4	111.6	116.7
PAT before MI	308.5	375.8	373.8	390.5
Minority Interest	8.6	1.7	9.3	9.8
PAT	299.8	374.2	364.4	380.8
Growth (%)	23.8	24.8	-2.6	4.5
EPS (Adjusted)	39.5	49.2	48.0	50.1

Source: Company, ICICI Direct Research

Exhibit 11: Cash flow statement				
	₹ crore			
(Year-end March)	FY22	FY23	FY24E	FY25E
Profit/(Loss) after taxation	304.3	363.2	364.4	380.8
Add: Depreciation & Amortization	46.9	45.0	55.5	111.7
Net Increase in Current Assets	-96.0	-213.4	-94.3	-102.6
Net Increase in Current Liabilities	97.9	74.7	24.5	25.8
Others	-16.5	2.2	12.6	12.6
CF from Operating activities	336.8	271.7	362.8	428.3
(Purchase)/Sale of Fixed Assets	-91.2	-193.8	-200.0	-150.0
Investments	-76.5	-141.3	0.0	0.0
Others	-124.9	117.1	-0.5	-0.5
CF from Investing activities	-292.6	-217.9	-200.5	-150.5
Proceeds from Preference shares	-0.8	0.0	0.0	0.0
(inc)/Dec in Loan	-16.6	2.9	0.0	0.0
Dividend & Dividend tax	-22.7	-30.3	-22.8	-22.8
Other	-0.7	-0.8	-12.6	-12.6
CF from Financing activities	-40.7	-28.2	-35.4	-35.4
Net Cash Flow	3.4	25.6	126.8	242.3
Cash and Cash Equivalent	459.6	463.0	493.5	620.3
Cash	463.0	488.6	620.3	862.6
Free Cash Flow	245.6	77.9	162.8	278.3

Source: Company, ICICI Direct Research

Exhibit 12: Balance Sheet				
	₹ crore			
(Year-end March)	FY22	FY23	FY24E	FY25E
Equity Capital	15.2	15.2	15.2	15.2
Reserve and Surplus	1,468.8	1,865.3	2,206.9	2,564.9
Total Shareholders funds	1,483.9	1,880.5	2,222.1	2,580.1
Total Debt	2.1	5.2	5.2	5.2
Minority Interest	26.0	26.8	26.8	26.8
Deferred Tax Liability	0.0	0.0	0.0	0.0
Other Non Current Liabilities	17.6	15.5	16.2	17.0
Source of Funds	1,529.6	1,927.9	2,270.3	2,629.1
Gross Block - Fixed Assets	450.6	488.9	703.9	868.9
Accumulated Depreciation	164.1	209.1	264.5	376.3
Net Block	286.6	279.8	439.3	492.6
Capital WIP	17.7	220.7	205.7	190.7
Fixed Assets	304.3	500.5	645.0	683.3
Investments	89.0	229.7	229.7	229.7
Other non-Current Assets	97.2	65.9	67.2	68.6
Inventory	227.3	288.2	322.5	358.5
Debtors	320.1	394.1	443.1	498.1
ST Loans and Advances	0.0	0.0	0.0	0.0
Other Current Assets	235.5	219.5	230.5	242.0
Cash	463.0	493.5	620.3	862.6
Total Current Assets	1,245.9	1,395.3	1,616.4	1,961.3
Creditors	163.2	164.4	183.9	204.5
Provisions	2.6	0.0	0.0	0.0
Other Current Liabilities	41.0	99.1	104.0	109.2
Total Current Liabilities	206.7	263.5	288.0	313.7
Net Current Assets	1,039.1	1,131.8	1,328.4	1,647.6
Application of Funds	1,529.6	1,928.0	2,270.4	2,629.2

Source: Company, ICICI Direct Research

Exhibit 13: Key ratios				
(Year-end March)	FY22	FY23	FY24E	FY25E
Per share data (₹)				
Reported EPS	39.5	49.2	48.0	50.1
Cash EPS	41.6	53.2	52.3	61.8
BV per share	195.3	247.4	292.4	339.5
Cash per Share	60.9	64.9	81.6	113.5
Dividend per share	4.0	2.0	3.0	3.0
Operating Ratios (%)				
Gross Profit Margins	56.1	54.8	55.0	55.5
EBITDA margins	31.1	30.0	29.8	30.3
PAT Margins	23.6	25.5	22.1	20.5
Cash Conversion Cycle	134.0	166.2	166.2	166.2
Asset Turnover	2.8	3.0	2.3	2.1
EBITDA conversion Rate	85.3	61.7	73.9	76.4
Return Ratios (%)				
RoE	20.2	19.9	16.4	14.8
RoCE	25.3	23.4	21.9	19.8
RoIC	34.9	37.5	33.9	31.7
Valuation Ratios (x)				
P/E	17.7	14.2	14.6	14.0
EV / EBITDA	12.2	10.6	9.3	7.7
EV / Net Sales	3.8	3.2	2.8	2.3
Market Cap / Sales	4.2	3.6	3.2	2.9
Price to Book Value	3.6	2.8	2.4	2.1
Solvency Ratios				
Debt / EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	3.8	3.4	3.5	3.5

Source: Company, ICICI Direct Research

Exhibit 14: ICICI Direct Coverage Universe (Healthcare)

Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				EV/EBITDA(x)				RoCE (%)			RoE (%)				
						FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E
Hospitals																					
Apollo Hospitals	APOHOS	4610	5,460	Buy	66383	59.1	60.5	80.2	126.8	30.2	31.6	25.8	18.8	15.1	14.1	16.6	21.8	15.1	13.8	16.0	21.1
Narayana Hrudalaya	NARHRU	844	990	Buy	17219	16.7	29.7	27.0	32.0	26.9	18.0	16.1	13.7	20.5	25.2	19.1	19.4	23.0	28.4	20.7	19.8
Shalby	SHALIM	136	170	Buy	1473	5.4	6.3	8.2	10.3	12.8	10.9	8.1	6.7	8.4	9.9	11.8	13.9	6.7	7.4	8.9	10.2
Aster DM	ASTDM	270	280	Buy	13500	10.5	8.6	18.1	23.6	10.1	9.3	6.2	4.7	9.0	8.7	13.6	15.4	13.3	9.8	17.1	18.2
Healthcare Global	HEAGLO	302	390	Buy	4198	3.9	2.1	6.4	8.6	20.8	16.4	12.3	10.6	5.0	8.1	12.5	14.3	5.0	3.4	9.4	11.2
Rainbow Children's Medicare	RAICHI	955	900	Hold	9742	13.6	20.8	19.2	20.2	30.3	26.4	24.6	20.9	20.2	17.8	14.5	16.5	22.9	19.9	15.5	14.0
Company																					
Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				P/E(x)				RoCE (%)			RoE (%)				
						FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E	FY22	FY23E	FY24E	FY25E
MNC Pharma																					
Abbott India	ABBIND	21901	20,315	Hold	45993	380.3	452.1	501.7	564.3	57.6	48.4	43.7	38.8	36.6	38.7	34.1	31.0	28.3	29.8	26.1	23.6
P&G Health	MERLIM	5135	5,620	Buy	8729	113.2	152.2	144.4	165.2	45.3	33.7	35.6	31.1	39.8	43.7	34.5	33.6	31.2	33.2	26.5	25.7
Sanofi India	SANOFI	6850	6,270	Hold	15755	410.6	269.8	251.4	272.7	16.7	25.4	27.3	25.1	33.3	55.1	49.6	45.0	25.9	41.2	36.9	33.3
Pfizer	PFIZER	3806	3,830	Hold	17505	133.2	135.6	135.7	147.2	28.6	28.1	28.0	25.8	26.1	24.8	22.7	21.6	21.4	18.4	17.1	16.3
Pharma																					
Ajanta Pharma	AJAPHA	1290	1,520	Buy	16514	55.7	46.5	59.9	69.2	23.2	27.7	21.5	18.6	27.0	21.3	23.5	23.3	21.8	17.4	19.2	18.9
Alembic Pharma	ALEMPHA	546	530	Hold	10764	27.7	17.4	14.1	22.1	19.7	31.5	38.8	24.7	10.6	8.6	8.0	11.6	10.4	7.8	6.2	9.1
Aurobindo Pharma	AURPHA	615	525	Hold	36030	47.4	34.8	46.2	52.4	13.0	17.6	13.3	11.7	12.9	10.2	12.6	13.1	11.3	7.7	9.3	9.6
Biocon	BIOCON	239	235	Hold	28758	5.7	5.7	8.8	15.4	42.1	42.0	27.2	15.6	7.5	3.9	5.6	6.8	8.1	3.8	5.6	9.0
Zydus Lifesciences	CADHEA	508	600	Buy	52045	21.0	21.6	25.3	33.3	24.2	23.5	20.1	15.3	12.0	14.2	14.8	14.9	12.6	12.6	13.1	14.8
Cipla	CIPLA	951	1,090	Buy	76774	32.9	36.4	42.7	48.2	28.9	26.1	22.3	19.7	16.7	17.4	17.8	18.2	12.7	12.5	13.2	13.4
Dr Reddy's Lab	DRREDD	4531	5,520	Buy	75214	127.2	269.3	230.2	256.5	35.6	16.8	19.7	17.7	12.5	23.9	18.8	21.1	11.0	19.2	14.4	14.2
Glenmark	GLEPHA	591	580	Hold	16677	42.7	37.8	34.6	41.3	13.8	15.7	17.1	14.3	14.8	13.4	13.5	14.9	13.2	11.2	9.4	10.1
Ipca Lab	IPCLAB	684	885	Hold	17385	34.8	20.8	31.4	37.0	19.7	32.9	21.8	18.5	17.4	12.1	15.7	16.5	16.1	8.9	12.1	12.7
Lupin	LUPIN	780	725	Hold	35488	11.9	8.3	25.6	33.0	65.7	93.8	30.4	23.7	3.4	5.7	11.0	13.0	4.4	3.0	8.6	10.2
Natco	NATPHA	630	565	Hold	11525	9.3	36.3	40.3	30.2	67.8	17.3	15.6	20.8	4.6	15.9	16.5	11.6	4.0	13.9	13.6	9.4
Sun Pharma	SUNPHA	970	1,140	Buy	232679	32.0	36.1	35.8	40.8	30.3	26.9	27.1	23.8	18.2	15.3	15.5	15.8	16.0	15.5	13.6	13.7
Torrent Pharma	TORPHA	1700	1,720	Hold	57468	32.0	36.3	45.1	53.8	53.1	46.8	37.7	31.6	19.7	17.1	20.4	23.3	18.2	17.9	19.0	19.4
Indoco Remedies	INDREM	335	405	Buy	3080	16.8	15.6	21.3	27.1	19.9	21.5	15.8	12.4	17.5	12.7	15.8	18.9	17.1	14.0	16.5	17.9
Caplin Point	CAPPOI	735	900	Buy	5586	39.5	49.2	48.0	50.1	18.6	14.9	15.3	14.7	25.3	23.4	21.9	19.8	20.2	19.9	16.4	14.8
Advanced Enzyme	ADVENZ	274	310	Hold	3068	11.5	13.1	10.7	10.7	23.7	21.0	25.7	25.7	14.3	10.9	13.4	14.2	11.0	8.7	10.7	11.3
Hester Bios	HESPHA	1651	1,490	Reduce	1486	45.7	31.1	40.5	53.3	36.1	53.1	40.8	31.0	10.9	7.5	8.8	10.3	15.0	9.4	11.2	13.1
API/CRAMS																					
Divis Lab	DIVLAB	3514	3,575	Buy	93121	111.5	68.7	78.3	89.4	31.5	51.2	44.9	39.3	30.2	17.8	18.9	19.4	25.2	14.3	14.8	15.2
Hikal	HIKCHE	284	375	Hold	3493	13.0	5.7	14.6	20.7	21.8	49.9	19.5	13.7	13.6	7.2	14.3	17.7	15.0	6.3	14.1	17.0
Syngene International	SYNINT	718	740	Buy	28794	9.9	11.6	13.3	17.9	72.7	62.0	53.9	40.2	11.7	13.8	14.2	16.9	12.9	12.8	13.0	14.9
Granules India	GRANUL	277	360	Buy	3405	16.6	20.8	21.8	27.8	16.6	13.3	12.7	10.0	15.6	18.5	17.8	19.4	16.0	18.2	16.2	17.3
Laurus Labs	LAULAB	335	300	Hold	17981	15.4	14.7	10.5	10.5	21.7	22.7	31.9	31.9	21.3	19.8	14.6	16.0	24.7	19.6	12.4	13.5
Suven Pharma	SUVPH	477	530	Buy	12164	17.8	14.7	17.7	20.0	26.8	32.4	27.0	23.8	37.5	26.0	25.6	24.5	29.7	20.6	20.5	19.5

Source: ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar -Inter CA, Kushal Shah -CFA L1, CFP, Utkarsh Jain -MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.